多发性硬化症市场[按药物类型，（免疫抑制剂（Lemtrada，ocrelizumab，Zinbryta和Aubagio）;免疫调节剂（Ampyra，Copaxone，Betaseron / extavia，Gilneya，Avonex / Plegrivey，Tysabri，Rebif，Tecifidera））;通过给药途径（可注射剂，口服剂）];和地理 - 趋势，分析和预测直到2025年

报告摘要

The Global Multiple Sclerosis Market Size is majorly driven by the factors such as rising number of consolidations between the market players for exploring the untapped market opportunity across the world.

多发性硬化(MS)是一种疾病insulating covers of nerves and spinal cord are damaged. These damages disrupt the functioning of nervous system, which results in double vision, muscles weakness, blindness in one eye, and trouble with sensation & coordination. The cause of MS is not clear, but the underlying mechanism causes either destruction to the immune system or failure of myelin-production cells in the body. Generally, MS is diagnosed with the presenting signs, symptoms and the result of supporting medical tests.

多发性硬化是四种类型;'复发 - 延长多发性硬化症'（RRMS），'二次逐步多发性硬化'（SPMS），'初步逐渐进行多发性硬化症（SPM）'，并“渐进式复发多发性硬化”（PRMS）。二次逐步多发性硬化是最常见的MS，通常在15-60岁之间的成年人造成的。同样，儿童和青少年也可能受到儿科硕士的影响，估计约有10,000名儿童和青少年被诊断为MS，并且具有这种疾病的一种症状。此外，多发性硬化基础报告了大约250万人在全球患有MS。

Evolving competitive landscape, increasing research and development for understanding the root cause of multiple sclerosis and increasing awareness for multiple sclerosis in all the age groups to support the growth of this market globally

全球多发性硬化市场的增长主要是通过越来越多的患有多发性硬化症的个体驱动。此外，最近过去的一些显着变化用于治疗RRMS，以及治疗多发性硬化症的连续药物发育也有望帮助该市场的增长。此外，2012-2013年的Aubagio等口腔药物被启动，因为它们在治疗各个年龄群体的多发性硬化时具有适当的作用，并且偏好转向不同和久坐的生活方式。这些因素与发展中经济体的提高医疗基础设施相结合，将在预测期间激增全球多发性硬化的全betway体育亚洲版入口球市场。

然而，如果MS可能会在预测期间妨碍这个市场的增长，那么治疗的成本和对原因的不明确。

全球多发性硬化市场Taxonomy

全球多发性硬化市场规模是在药物类型，行政途径和地理的基础上进行细分。

On the basis of drug type, market is segmented into:

• 免疫抑制剂
  • Lemtarda.
  • ocrelizumab.
  • Zinbryta.
  • Aubagio
• 免疫调节剂
  • ampyra.
  • Capxone.
  • betaseron / extavia
  • 吉尔尼
  • Avonex / PleGridy
  • tyasabri.
  • reb
  • Teucifidera.

在管理类型的途径的基础上，市场被分段为：

• Injectable Agents
• Oral Agents

多发性硬化症市场，用药物类型分为免疫抑制剂和免疫调节剂

越来越多的变化，了解多发性硬化，以促进全球市场的免疫调节器市场。

The immunomodulators segment is further segmented into Ampyra, Capxone, Betaseron/Extavia, Gilneya, Avonex/Plegridy, Tyasabri, Rebif, and Teucifidera The global immunomodulators market is primarily driven by the increasing preference and awareness for the use of biologic drugs as they have been resulting to be the most effective treatment in some past year. Thus, increased preference of biologics would spur the market of immunomodulators in the multiple sclerosis market during the forecast period.

地理位置上，全球市场分为北美，欧洲，亚太地区，拉丁美洲和中东和非洲。

Increased expenditure on R&D for developing new and effective treatments on multiple sclerosis (MS) to lead the multiple sclerosis在北美地区。

North America is expected to dominate the multiple sclerosis market share over the forecast period. It holds major share owning to the increasing research and development by the large pool of players in the market. Moreover, the rising preference for biological drugs to boost the market in North America.

然而，由于增加对多发性硬化症的诊断，以及发展中国，日本和印度等发展中国家的医疗保健基础设施，亚太地区以速度增长更快。betway体育亚洲版入口

全球多发性硬化症的主要球员市场是：

• Hoffmann-La Roche Ltd.
• Bayer Healthcare AG
• Teva Pharmaceuticals.
• glaxosmithkline.
• ABBVIE Inc.
• Sonafi Pasteur.
• Pfizer Inc.
• 默克和公司
• Novartis AG
• AB Science
• Opexa